<i>De novo</i> CD5‐positive diffuse large B‐cell lymphoma: clinical characteristics and therapeutic outcome

• Motoko Yamaguchi

• Toshiyuki Ohno

• Kouji Oka

• Masanori Taniguchi

• Motohiro Ito

• Kenkichi Kita

• Hiroshi Shiku

抄録

To determine the clinical significance of CD5 expression in diffuse large B‐cell lymphoma (DLBL) without a clinical history of low‐grade B‐cell lymphoma, we have reviewed the clinical features and therapeutic outcome of 25 patients with de novo CD5‐positive DLBL, and compared the results with those of 87 patients with CD5‐negative DLBL and 22 patients with mantle cell lymphoma (MCL). The patients with de novo CD5‐positive DLBL had clinical characteristics of elderly onset (median age 63, range 37–91), and female predominance (male/female 10/15). 21 (84%) of these patients had extranodal involvement at presentation, with great variation in the sites. In comparison with the patients with CD5‐negative DLBL, the treatment outcome for the patients with de novo CD5‐positive DLBL was very poor with frequent relapse. The failure‐free survival curve was almost identical to that of patients with MCL, showing that standard chemotherapy for DLBL was not effective for most of the patients with de novo CD5‐positive DLBL. These findings suggest that de novo CD5‐positive DLBL forms a distinct subgroup of DLBL.

収録刊行物

• British Journal of Haematology

  British Journal of Haematology 105 (4), 1133-1139, 1999-06

  Wiley

キーワード

• Hematology

詳細情報

• CRID: 1360011144204636672
• NII論文ID: 30014738434
• DOI: 10.1046/j.1365-2141.1999.01513.x
• ISSN: 13652141
• ISSN: 00071048
• Web Site: https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2141.1999.01513.x
• Web Site: https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2141.1999.01513.x
• データソース種別:
  • Crossref
  • CiNii Articles